FDA Approves Teva's TREANDA® (bendamustine HCI) Injection, a New Liquid ... DailyFinance TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia ... |
